Adial Pharmaceuticals gets Nasdaq notice for falling below $2.5 million stockholders’ equity minimum
ADIL•Planned steps to restore equity
- Adial expects to seek shareholder approval to convert Series A Non-Voting Convertible Preferred Stock to help restore equity.
Nasdaq notice and compliance timeline
- Adial Pharmaceuticals received a Nasdaq notice on Aug. 18, 2026, for falling below the $2.5 million minimum stockholders’ equity requirement.
- Nasdaq flagged that the company also fails alternative listing tests tied to market value of listed securities or net income thresholds.
- Shares continue trading for now; the company has until Oct. 2, 2026, to submit a compliance plan.
- Nasdaq could grant up to 180 days from Aug. 18, 2026, to regain compliance; failure could trigger delisting proceedings.
